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Received 28 October 2008; received in revised form 24 July 2009; accepted 26 July 2009Abstract Human embryonic stem cell (hESC) pluripotency has been reported by several groups to be best maintained by
culture under physiological oxygen conditions. Building on that finding, we inhibited complex III of the mitochondrial respiratory
chain using antimycin A or myxothiazol to examine if specifically targeting the mitochondria would have a similar beneficial
result for the maintenance of pluripotency. hESCs grown in the presence of 20 nM antimycin A maintained a compact
morphology with high nuclear/cytoplasmic ratios. Furthermore, real-time PCR analysis demonstrated that the levels of Nanog
mRNA were elevated 2-fold in antimycin A-treated cells. Strikingly, antimycin A was also able to replace bFGF in the media
without compromising pluripotency, as long as autocrine bFGF signaling was maintained. Further analysis using low-density
quantitative PCR arrays showed that antimycin A treatment reduced the expression of genes associated with differentiation,
possibly acting through a ROS-mediated pathway. These results demonstrate that modulation of mitochondrial function results
in increased pluripotency of the cell population, and sheds new light on the mechanisms and signaling pathways modulating
hESC pluripotency.
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The mechanisms underlying the maintenance of hESC self-
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Both leukemia inhibitory factor (LIF) and bone morphogenetic
protein 4 (BMP 4) play important roles in the maintenance of
mESC self-renewal via activation of Stat3 (Matsuda et al.,
1999; Niwa et al., 1998; Ying et al., 2003). Conversely, LIF is
not sufficient to maintain pluripotency of hESC (Daheron et
al., 2004) and addition of BMP 4 to the culturemedia results in
rapid differentiation (Xu et al., 2002). Instead, the combined
actions of basic fibroblast growth factor (bFGF, FGF2) and.
143Mitochondria and embryonic stem cell pluripotencyTGFβ/Activin/Nodal signaling pathways are believed to be
critical to hESC self-renewal. Nearly all formulations for the
routine culture of hESCs include exogenous bFGF, demon-
strated to increase the cloning efficiency of hESCs maintained
under serum-free conditions (Amit et al., 2000). When added
at high concentrations bFGF supports hESC self-renewal under
feeder-free conditions in the presence (Rosler et al., 2004; Xu
C et al., 2005) or absence of conditioned media (Xu C et al.,
2005). Several studies have also shown that the combined
activities of Noggin and bFGF maintain hESC self-renewal in
the absence of conditioned medium due to the suppression of
BMP activity (Wang et al., 2005; Xu RH et al., 2005).
Furthermore, Activin or Nodal appear to cooperate with
bFGF to maintain hESC pluripotency in chemically defined
media (Vallier et al., 2005).
In addition to media constituent requirements Ezashi et
al. (Ezashi et al., 2005) demonstrated that culture of hESCs
under low oxygen (O2) tension (5%) reduced the appearance
of spontaneous differentiation. This may be the normal
physiological state, as early-stage mammalian embryos also
develop under low O2 concentrations (1.5–5.3%) until they
implant in the uterine endometrium, when O2 levels increase
with vascularization (Fischer and Bavister, 1993). When
cultured under low O2 tension, mammalian cells decrease
ATP production via oxidative phosphorylation in the mito-
chondria and increase glycolytic functions in order to meet
energy demands. Studies of mitochondrial number and
morphology in hESCs have demonstrated that undifferenti-
ated hESCs have relatively few mitochondria in the cyto-
plasm and these mitochondria have few christae, an
indication of immature morphology (St John et al., 2005;
Oh et al., 2005; Cho et al., 2006). As hESCs differentiate the
number of mitochondria with a mature morphology
increases, concomitant with the ATP levels produced by
oxidative phosphorylation (Cho et al., 2006). Taken togeth-
er, these results suggest that inhibition of mitochondrial
function may prevent differentiation, and thus modulate the
maintenance of pluripotency.
In this study we tested this hypothesis by specifically
inhibiting complex III of the mitochondrial respiratory chain
using antimycin A, an antibiotic isolated from Streptomyces
sp. Antimycin A specifically blocks the flow of electrons from
semiquinone to ubiquinone in the quinone cycle of complex
III, thus disrupting the proton gradient across the inner
membrane of mitochondria and preventing O2 consumption
at complex IV as well as ATP formation. Complex III is also
known to be a source of reactive oxygen species (ROS)
production in the cell; predominantly superoxide anion (O2- ),
which when produced in moderate amounts activates
hypoxic signaling pathways in the cell. Consequently,
complex III is considered the O2 sensor of the cell (Chandel
et al., 2000; Guzy et al., 2005). Antimycin A treatment
simultaneously decreases ATP production via oxidative
phosphorylation and increases ROS formation.Results
Antimycin A (20 nM) was added 48 h after passaging to hESC
cultures (WA07) growing on mouse embryonic fibroblast
feeder cells (MEFs) in standard culture media, and this
treatment was maintained for 5 days (Fig. 1). hESCs grownunder these conditions maintained a typical compact
morphology with high nuclear-cytoplasmic ratio and colonies
with well-defined borders, comparable to those in control
cells (data not shown). To quantify the levels of pluripo-
tency, we used real-time PCR for the well-characterized
pluripotency transcription factors Nanog and POU5F1 (also
known as Oct-4). hESCs treated with antimycin A showed a 2-
fold increase in Nanog mRNA levels compared with control
cells (Fig. 1a, Pb0.01, n=6). Oct-4 mRNA levels were not
statistically different (Fig. 1a). Similar results were obtained
with the complex III inhibitor, myxothiazol, used at a
concentration of 20 nM (data not shown).
To determine if the effects observed after addition of
antimycin A to the culture media were sustained or only
transient, hESCs were maintained for several passages (1–2
months) in the presence of antimycin A. hESCs grown under
these conditions maintained good morphology throughout
(Fig. 1d) and maintained a 2-fold elevation of Nanog mRNA
(Pb0.05, n=3) relative to controls. Again, Oct-4 mRNA levels
were not significantly different from controls (Fig. 1a).
Western blot analysis of these extended treatment cells
showed that Nanog protein levels were also increased in
antimycin A-treated cells (Fig. 1b); Oct-4 protein levels were
not significantly different between treatments (Fig. 1c). To
ensure that prolonged antimycin A treatment did not
negatively impact the pluripotent phenotype, we character-
ized these cells by ICC for the pluripotency markers Oct-4,
Nanog, and SSEA-4. Nanog and Oct-4 were both found in the
nucleus of antimycin A-treated cells, and the cell surface
marker SSEA-4 labeled colonies (Fig. 1d) similar to control
cells.
To determine if antimycin A-treated cells retained the
potential to differentiate in vivo, we injected hESCs treated
with antimycin A for 9 passages into NOD/SCID mice to test
their ability to form teratomas. Similar to hESCs maintained
under standard conditions (not shown), antimycin A-treated
cells were able to form teratomas exhibiting tissues of all
three germ layers (Fig. 1e), including gastrointestinal tissue
(endoderm), cartilage (mesoderm), and neuro ganglia
(ectoderm). Finally, cells grown for extended periods (19
passages) in the presence of antimycin A also maintained a
stable 46 XX karyotype (data not shown).
To exclude the possibility that the effect of antimycin A
on Nanog expression was due to an increase in cell survival of
pluripotent stem cells relative to differentiated cells, the
levels of annexin V/PI-positive cells were determined by flow
cytometry (Figs. 2a–c). There was no statistically significant
difference in the percentage of viable cells between control
(83.25±2.15, Figs. 2a and c) and antimycin A (81.2±9.9,
Figs. 2b and c)-treated cells. Based on these results
antimycin A does not appear to affect cell survival.
In addition, proliferation of hESCs was determined by
BrdU incorporation into genomic DNA during the S phase of
the cell cycle (Figs. 2d and e). No statistically significant
difference was observed in the percentage of cells that
incorporate BrdU between control and antimycin A-treated
cells. In combination with the above results, antimycin A
does not seem to affect cell death or proliferation of hESCs.
As discussed above, bFGF is a well-described factor
important in the maintenance of pluripotency in hESCs,
even supporting pluripotency in the absence of feeder cells
or conditioned media when present at high concentrations
Figure 1 Analysis of pluripotency after antimycin A treatment. (a) Real-time PCR for the pluripotency markers Nanog and Oct-4 in
hESC treated with antimycin A for 5 days or 4–8 passages. Statistically significant differences were determined by paired t test; n=6
and 3, respectively. ⁎⁎Pb0.01; ⁎Pb0.05. (b,c) Western blot analysis for Nanog and Oct-4 protein levels in hESCs treated with antimycin
A for 4–8 passages. (d) hESC morphology and pluripotency marker pattern expression after treatment with antimycin A for 4–
8 passages, examined by phase contrast microscopy, ICC, and confocal laser scanning microscopy. (e) H and E staining of teratoma
sections from hESCs treated with antimycin A for 9 passages. Abbreviations: Ant A, antimycin A; error bars, SEM. Scale bar, 50 μm.
144 S. Varum et al.(Wang et al., 2005; Xu et al., 2005). In order to better
understand the beneficial effect of antimycin A we cultured
hESCs on mouse feeders for 7 days using different combina-
tions of antimycin A and bFGF and assayed Oct-4 expression
by ICC. Colonies were divided into three categories according
to the pattern of Oct-4 expression and quantified: totally
positive colonies in which the majority of cells were positive
for Oct-4 (Fig. 3a bottom left); partially positive colonies
containing a significant quantity of both positive and
negative cells (Fig. 3a bottom center); and negative colonies
in which the majority of cells were negative for Oct-4 (Fig. 3a
bottom right). At least 200 colonies were counted per
treatment. As expected, removal of bFGF from the media
resulted in a significant decrease in the number of totally
positive colonies and an increase in the number of partially
positive colonies (Fig. 3b; Pb0.001), confirming the impor-
tance of this growth factor in the maintenance of healthy
hESC colonies. Interestingly, when antimycin A was added to
culture media lacking bFGF the numbers of totally positive
colonies (65.9% vs 67.0%) and partially positive colonies
(33.3% vs 32.6%) were indistinguishable from those under
standard culture conditions (Fig. 3b), suggesting thataddition of antimycin A maintains Oct-4 expression levels
in culture conditions lacking bFGF. Surprisingly, the addition
of both antimycin A and bFGF to the culture increased the
number of totally positive colonies (86.8% vs 67.07%,
Pb0.001). The answer to this apparent contradiction is
unknown but several factors may be involved. First, Western
blotting and real-time PCR are unbiased quantitative
analyses that probe an entire population of cells, while ICC
as carried out here was inherently qualitative in terms of
signal intensity, colony size, and colony heterogeneity (i.e.,
more or less positive cells in a colony), all of which could
have played a role. Furthermore, subcellular localization of
Oct-4 should also be considered. It is understood that during
early differentiation of hESC Oct-4 localizes primarily in the
cytoplasm instead of the nucleus, as is observed with
undifferentiated hESCs. During human development Oct-4
is first observed cytoplasmically before localizing to the
nucleus in the inner cell mass (Cauffman et al., 2005). In this
case cells in which Oct-4 localizes to the cytoplasm will be
counted as negative in our ICC analysis but would still be
positive by Western blotting. Subcellular localization of Oct-
4 may thus be a better assay of pluripotency than total
Figure 2 Analysis of apoptosis/necrosis and proliferation rates after antimycin A treatment. (a,b) Representative dot plots of flow
cytometry for annexin V/PI of control and antimycin A-treated hESCs. Four populations were identified: viable cells (negative for both
annexin V and PI); early apoptotic cells (positive for annexin V and negative for PI); late apoptoic cells (positive for both annexin V and
PI); and necrotic cells (only positive for PI). (c) Percentage of the different cell populations in both control and antimycin A-treated
cells, (d) BrdU incorporation in both control and antimycin A-treated hESCs, examined by confocal microscopy. (e) Percentage of
BrdU-positive cells. Error bars, SEM. Scale bar, 50 μm.
145Mitochondria and embryonic stem cell pluripotencycellular protein. Importantly, when performing double-
labeling experiments for both Oct-4 and Nanog, the most
striking effect of antimycin A treatment within single
colonies was an increase of Oct-4+/Nanog+ cells (97% vs
70%) at the expense of the Oct-4+/Nanog– subpopulation
(0.4% vs 23%). Finally, we performed real-time PCR for Nanog
in both WA07 (Fig. 3c) and WA09 (Supplemental Fig. 1,
carried out in a separate facility) for the conditions above.
We observed that both cell lines are responsive to bFGF
withdrawal demonstrated by a decrease in Nanog expression.In both cell lines antimycin A maintains Nanog expression on
bFGF withdrawal, suggesting that this effect is not related to
the particular characteristics of one hESC line.
One possible explanation for these results is that
antimycin A induces bFGF secretion by feeders and/or
hESCs. In order to address this point, bFGF concentration in
the culture media was measured by ELISA (Supplemental
Fig. 2). No bFGF secretion by mitomycin-inactivated
MEFs was detected. The bFGF initially present in the media
(4 ng/ml) was rapidly degraded/processed by the cells, as
Figure 3 Analysis of pluripotency after antimycin A treatment in the absence of bFGF. (a) Oct-4 expression pattern categories in
hESC analyzed by ICC and confocal laser scanning microscopy. (b) Percentage of totally positive, partially positive, and negative
colonies for Oct-4 in antimycin A-treated cells in the presence or absence of bFGF for 7 days. Three independent experiments were
performed, and at least 200 colonies total were analyzed per condition. Statistical significance was determined by chi-square test
⁎⁎⁎Pb0.001. (c) Real-time PCR for Nanog in hESCs treated with different combinations of antimycin A and bFGF for 7 days. Statistical
significance was determined by one-way ANOVA followed by Dunnet's multiple comparison test. ⁎Pb0.05. (d) Real-time PCR for Nanog
and Oct-4 in hESCs maintained on Matrigel for 7 days with different combinations of bFGF, antimycin A, and PD173074. Statistical
significance was determined by one-way ANOVA followed by Dunnet's multiple comparison test. ⁎⁎Pb0.01. (e) hESC morphology and
pluripotency marker pattern expression in cells treated with antimycin A in the absence of bFGF for 4–8 passages, analyzed as
described in Fig. 1d. (f) H and E staining of teratomas from hESCs treated with antimycin A in the absence of bFGF for 33 passages.
Abbreviations: Ant A, antimycin A; bFGF, basic fibroblast growth factor; (+), present; (–), absent. Error bars, SEM. Scale bar, 100 μm.
146 S. Varum et al.demonstrated in media concentrations of 65.92±5.01 and
24.41±3.58 pg/ml after 6 h or 24 h of culture, respectively
(Supplemental Fig. 2a). These results are in accordance with
the findings of Eiselleova et al. (Eiselleova et al., 2008) that
showed, in contrast to human feeders, MEFs do not produce
bFGF. Antimycin A treatment does not promote bFGFsecretion by the MEFs as media concentrations are indistin-
guishable from controls (59.04±3.94 and 27.31±7.89 pg/ml)
after 6 and 24 h of culture, respectively. In contrast to MEFs,
hESCs appear to secrete bFGF into the media, since
concentrations of 64.40±36.72 pg/ml of bFGF were detected
after 24 h of culture in media not supplemented with bFGF
147Mitochondria and embryonic stem cell pluripotency(Supplemental Fig. 2b). These results are in accordance with
the findings of Dvorak et al. (Dvorak and Hampl, 2005). bFGF
production by hESCs was not affected by antimycin A
treatment. These results indicate that the effect of antimycin
A on pluripotencywas not due to an increase in bFGF secretion
by the feeders or by hESCs themselves.Figure 4 Pluripotency gene expression after antimycin A treat
expression profiles were analyzed by the TaqMan array human ste
differences of genes involved in the maintenance of pluripotency. (a,
4, Nanog, and TDGF1. (b, left) Heat map for genes correlated with p
correlated with pluripotency. In this analysis an increase in expres
represented by the purple color. Abbreviations: Ant A, antimycin A;
Statistically significant differences were determined by one-way
independent experiments were performed. Error bars, SEM. ⁎⁎Pb0.0These findings raise questions regarding the involvement
of the bGF pathway in this effect. To address this issue we
used the bFGF receptor inhibitor PD173074 (Mohammadi et
al., 1998). hESCs were maintained on Matrigel for 7 days in
different combinations of bFGF, PD173074, and antimycin A
(Fig. 3d). Similar to what we observed for hESCs cultured onment in the presence or absence of bFGF Pluripotency gene
m cell pluripotency panel. (a, left) Heat map for fold change
right) Bar graph of the fold changes differences observed for Oct-
luripotency. (b right) Bar graph of fold change averages of genes
sion is represented by the yellow color, whereas a decrease is
bFGF, basic fibroblast growth factor; (+) presence; (–) absence.
ANOVA followed by Dunnet's multiple comparison test. Three
1.
148 S. Varum et al.feeders, bFGF removal reduced Nanog expression (1.6-fold
decrease) when compared to control cells (bFGF alone).
Moreover, the addition of PD173074 promoted a significant
decrease in Nanog and Oct-4 expression when compared to
control cells (2.8- and 2.1-fold decrease, respectively).
These results are in accordance with the findings of Dvorak et
al. (Dvorak et al., 2005) who demonstrated a crucial role for
the autocrine bFGF signaling pathway in the maintenance of
hESC self-renewal. Treatment with antimycin A in the
absence of bFGF maintained Nanog and Oct-4 mRNA
expression at similar levels to controls; however, the
expression of these markers decreased significantly on the
addition of PD173074 (1.8- and 1.96-fold decrease for Nanog
and Oct-4, respectively). Interestingly, the decrease in
Nanog mRNA levels after the addition of PD173074 was less
accentuated in the presence of antimycin A, perhaps
suggesting that antimycin A functions through a different
pathway than bFGF. These results indicate that, although
antimycin A can maintain the expression levels of pluripo-
tency markers in the absence of exogenous bFGF, it cannot
maintain pluripotency when the endogenous bFGF pathway is
inhibited, reinforcing the importance of the autocrine bFGF
signaling pathway. Additionally, since antimycin A mitigated
the effects of both exogenous bFGF removal and the
inhibition of the endogenous bFGF pathway by PD173074, it
is likely that antimycin A acts in a pathway separate from
bFGF.
To determine if cells treated with antimycin A remain
pluripotent in the absence of bFGF for prolonged periods of
time, hESCs were treated with antimycin A in knockout
media without bFGF for periods greater than 1 month. The
best colonies under all conditions were manually passaged
every 7 days. hESCs maintained under these conditions had a
similar morphology to control cells, including tightly packed
cells in colonies with well-defined borders (Fig. 3e).
Immunocytochemical analysis demonstrated that these
cells express the pluripotency markers Nanog, Oct-4, and
SSEA-4 in similar patterns to control cells (Fig. 3e). We also
evaluated the capacity of these cells to differentiate in vivo.
Antimycin A-treated cells grown in the absence of exogenous
bFGF (33 passages) generated teratomas exhibiting tissues
from all three germ layers (Fig. 3f). These cells maintained a
stable 46XX karyotype after prolonged culture (19 passages,
data not shown).
To further investigate the role of antimycin A treatment
on gene expression we used the TaqMan low-density array
human stem cell pluripotency panel. These arrays contain 90
genes involved in maintenance of pluripotency or promotion
of differentiation, along with 6 endogenous control genes
(Adewumi et al., 2007). We maintained hESCs in different
combinations of antimycin A and bFGF for more than 20
passages, and analyzed mRNA levels by real-time PCR.Figure 5 Differentiation gene expression after antimycin A treatm
expression profiles were analyzed by the TaqMan array human stem
differences of differentiation genes involved in endoderm, mesoderm
of fold changes average of differentiation genes involved in endode
analysis an increase in expression is represented by the yellow c
Abbreviations: Ant, antimycin A; bFGF, basic fibroblast growth facto
were determined by one-way ANOVA followed by Dunnet's multiple co
Error bars, SEM. ⁎⁎Pb0.01.Among the genes analyzed were Nanog (Chambers et al.,
2003; Mitsui et al., 2003), POUF51 (Nichols et al., 1998), and
TDGF1 (Baldassarre et al., 1996), all critical for the
maintenance of pluripotency. Consistent with our findings
using single gene assays, treatment with antimycin A in the
presence of bFGF resulted in a statistically significant 2-fold
increase in Nanog expression, when analyzed with the low-
density array (Fig. 4a; n=3; Pb0.01). This difference was
maintained in the absence of bFGF (Pb0.01). TDGF1 was also
significantly elevated after treatment with antimycin A (1.8-
fold increase; Pb0.01), while POU5F1 was elevated but not
significantly. Both TDGF1 and POU5F1 were elevated in the
absence of bFGF but did not rise to the level of significance.
The other four pluripotency genes (SOX2, DMNT3B, GABRB3,
and GDF3) on the array were not elevated and, surprisingly,
removal of both antimycin A and bFGF did not significantly
reduce expression levels of any of these genes (Fig. 4a,
heatmap). When 32 genes correlated with pluripotency were
examined, several genes were found to be amplified (Fig. 4b,
heatmap), including EBAF, LEFTB, and NODAL, but several
others decreased with antimycin A treatment including GBX2
and CRABP2. To compare these genes as a group across
treatments, we averaged the fold changes across all 32
genes. No significant differences in the expression of these
pluripotency correlated genes were observed between any
treatments (Fig. 4b).
We also studied the expression of genes involved in
differentiation. These genes were grouped according to their
participation in endoderm (Fig. 5a), mesoderm (Fig. 5b),
trophoblast (Fig. 5c), or ectoderm (Fig. 5d) differentiation
and averaged as above. Antimycin A treatment in the
absence of bFGF resulted in no statistical differences in the
expression of differentiation genes in comparison to control
cells (Figs. 5a–d). The addition of antimycin A in the
presence of bFGF reduced the expression of differentiation
genes in all categories (Figs. 5a–c), although only the
decrease in ectoderm related genes was statistically
significant (Fig. 5d, Pb0.01, n=3). These results are in
accordance with the findings of Vallier et al. (Vallier et al.,
2009) who reported that Nanog overexpression prevents
neuroectoderm differentiation. In contrast to the pluripo-
tency genes whose expression did not change after with-
drawal of bFGF and antimycin A, endoderm, trophoblast, and
mesoderm genes were all significantly higher in the absence
of these compounds (Figs. 5a–c; Pb0.01, n=3). Only the
ectodermal genes were unchanged in the absence of bFGF
and antimycin A (Fig. 5d). This last result is in accordance
with Stern (Stern, 2005) who reported that bFGF plays a
crucial role in neuroectoderm specification in amphibian and
chick embryos.
Antimycin A traditionally stimulates a shift in the
metabolism from oxidative phosphorylation to glycolysisent in the presence or absence of bFGFs. Differentiation gene
cell pluripotency panel. (a–d left) Heat maps of fold change
, trophoblast, and ectoderm specification. (a–d right) Bar graphs
rm, mesoderm, trophoblast, and ectoderm specification. In this
olor, whereas a decrease is represented by the purple color.
r; (+) presence; (–) absence. Statistically significant differences
mparison test. Three independent experiments were performed.
149Mitochondria and embryonic stem cell pluripotency(due to lower mitochondrial function) and promotes an
increased superoxide generation at complex III (due to a lack
of normal electron flow to oxygen, and thus the “leaking” of
high-energy electrons from the transport chain). In order todetermine if antimycin A treatment has the same effect in
hESCs, the levels of adenine nucleotides (ATP, ADP, and AMP)
were measured by high-performance liquid chromatography
(HPLC) in control and antimycin A-treated hESCs. No
Figure 6 Energy metabolism analysis in antimycin A-treated
hESCs. (a) Adenylate pool in antimycin A-treated cells. In order
to determine the adenylate pool in the cell we performed
reverse-phase high-performance liquid chromatography (HPLC)
for ATP, ADP, and AMP. (b) Adenylate charge of antimycin A-
treated cells. Adenylate energy charge was determined accord-
ing to the following formula: ATP + 0.5ADP/(ATP+ADP+AMP). (c)
Percentage of LDH activity in antimycin A-treated cells.
Percentages were normalized to those found in control cells.
Statistically significant differences were determined by paired t
test. Three independent experiments were performed. Error
bars, SEM. ⁎Pb0.05.
150 S. Varum et al.significant differences in the adenylate pool or adenylate
charge were observed between the two conditions (Figs. 6a
and b). Lactate dehydrogenase (LDH) is an enzyme that
converts pyruvate, the final product of glycolysis, to lactate
when a decline in O2 availability or impaired ATP production
by mitochondria forces the cell into anaerobic metabolism,
or when aerobic glycolysis is favored, as is the case in someFigure 7 Superoxide anion generation in antimycin A-treated hESC
percentages of MitoSox Red-positive cells on treatments with differe
MitoSox Red-positive cells in control versus treated hESCs. Percentag
PCR for Nanog of hESCs treated with different combinations of antim
one-way ANOVA followed by Dunnet's multiple comparison test. Errocancers. Antimycin A-treated cells showed an increase of
approximately 40% in the rates of LDH activity (Fig. 6c).
These results indicate that antimycin A induces a shift in the
metabolism toward glycolysis similar to what is observed in
other cell types. However, hESCs cultured in the presence of
antimycin A maintained ATP levels consistent with untreated
cells.
As noted above, antimycin A increases the production of
ROS in cells. To determine the effect of antimycin A on
mitochondrial superoxide anion production in hESCs, we used
MitoSox Red (Fig. 7). Cells treated with 20 nM antimycin A
showed an increase of approximately 61±20.7% in the
number of positive cells for MitoSox Red when compared
with control cells, as monitored by flow cytometry. This
effect was dose dependent as treatment of hESCs with 2 μM
of antimycin A increased the number of positive cells
approximately 250±16.3%. This effect was counteracted by
the addition of MnTbap, a cell-permeable superoxide
dismutase (SOD) mimetic which acts as a scavenger
specifically targeting superoxide. Treatment with 50 μM
MnTbap eliminated the effect of treatment with 20 nM
antimycin A. MnTbap was also able to reduce the number of
positive hESCs under control conditions (Figs. 7a and b).
Reactive oxygen species are important signaling mole-
cules within the cell. To address whether the effect of
antimycin A on pluripotency is mediated by ROS cells were
maintained in different combinations of antimycin A and
MnTbap and real-time PCR for Nanog was performed (Fig.
7c). MnTbap was able to partially abrogate the antimycin A-
stimulated increase in Nanog expression, although no
significant differences were observed between control and
MnTbap-treated cells. These results suggest that superoxide
anion generated at complex III is at least partially respon-
sible for the effect of antimycin A on Nanog expression.
Discussion
Studies have demonstrated that hESCs cultured under low
oxygen tension (1.5–5%) are better maintained in the
undifferentiated state (Ezashi et al., 2005; Westfall et al.,
2008). This suggests that a decrease in mitochondrial
oxidative phosphorylation and an increase in ROS signaling
under these conditions might be involved. We show here that
this effect can be mimicked by directly inhibiting mitochon-
drial function in a way that is at least partially dependent on
ROS formation. hESCs treated with 20 nM antimycin A
maintained pluripotency not only as evidenced by immuno-
cytochemical staining of the pluripotency markers but also as
assayed by teratoma formation. Real-time PCR and Western
blot analysis demonstrated that antimycin A-treated hESCs
had elevated levels of both Nanog mRNA and protein. While a
similar increase was observed for TDGF1 mRNA expression,
no significant differences were observed for Oct-4 protein or
mRNA. These results can best be explained by considering
that, unlike the case for Oct-4, overexpression of Nanog iss. (a) Representative flow cytometry histograms demonstrating
nt combinations of antimycin A and MnTbap. (b) Percentages of
es were normalized to those found in control cells (c) Real-time
ycin A and MnTbap. Statistical significance was determined by
r bars, SEM. ⁎Pb0.05; ⁎⁎⁎Pb0.01.
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152 S. Varum et al.beneficial for the maintenance of pluripotency, namely
preventing neuroectoderm differentiation induced by FGF
signaling (Vallier et al., 2009). Others have shown that
overexpression of Nanog allows culture in the absence of
feeders (Darr et al., 2006) and circumvents the need for both
TGFb and FGF signaling in the maintenance of pluripotency
(Xu et al., 2008). In contrast Oct- 4 levels must be kept within
defined ranges in order to maintain self-renewal of both
mouse and human ESCs, as overexpression results in
upregulation of markers involved in endoderm and meso-
derm specification of both cell types (Rodriguez et al., 2007;
Niwa et al., 2000) while, conversely, RNA interference
targeting Oct-4 can trigger trophectoderm differentiation
(Hay et al., 2004; Velkey et al., 2003; Matin et al., 2004).
Additionally, Pan et al. (Pan et al., 2006) demonstrated that
a steady-state concentration of Oct-4 maintains Nanog
expression, whereas an elevated concentration of Oct-4
suppresses Nanog expression. Therefore, while upregulation
of Nanog is globally beneficial to the maintenance of
pluripotency, upregulation of Oct-4 can be detrimental and
maintenance of the status quo is appropriate for Oct-4
expression. Taking into account these findings it seems that
antimycin A does not increase Oct-4 expression above the
steady-state present in pluripotent hESCs.
Very few growth factors have been identified as being
necessary or sufficient for maintenance of hESC pluripo-
tency, though one leading candidate is bFGF (Amit et al.,
2000; Rosler et al., 2004; Xu et al., 2005). As bFGF and
antimycin A both promote pluripotency, we were interested
in determining if antimycin A could maintain pluripotency in
the absence of bFGF. Treatment with antimycin A was able
to alleviate the requirement for exogenous bFGF as there
was no difference in the number of totally positive colonies
between standard culture conditions and those including
antimycin A but lacking bFGF. Furthermore, antimycin A
was able to sustain Nanog expression on bFGF removal in
both WA07 and WA09 cell lines, demonstrating that the
effect is not ES line dependent. Antimycin A treatment
failed to maintain pluripotency on the inhibition of the
endogenous bFGF pathway, indicating the requirement for
the endogenous bFGF pathway in the maintenance of
pluripotency. The observation that antimycin A increases
Nanog expression even when the endogenous pathway is
suppressed suggests that antimycin A works through a
pathway other than bFGF. Taken together, our results
suggest that bFGF and antimycin A work through synergistic
pathways to maintain pluripotency.
Cells cultured for several months in the presence of
antimycin A and absence of exogenous bFGF remained
pluripotent as assessed by ICC and teratoma formation.
Furthermore, low-density array analysis showed that anti-
mycin A treatment of hESCs cultured in the absence of bFGF
resulted in an elevated expression of Nanog mRNA and
maintained the expression of differentiation genes at similar
levels to those found in control cells.
Our findings can be explained in light of morphological
and functional changes that mitochondria undergo during
early mammalian development. In the oocyte, mitochondria
are spherical with few christae, whereas between the zygote
and the morula stage, mitochondria become more elongated
(Ramalho-Santos et al., 2009). At the blastocyst stage two
distinct forms of mitochondria are present: mitochondria inthe inner cell mass (ICM) are spherical and have low O2
consumption, whereas those in the trophectoderm (TE) are
elongated and have higher respiratory rates (Stern et al.,
1971; Houghton, 2006). As hESCs are derived from the ICM,
one should expect that they share these metabolic and
morphological features. Indeed, it has been shown that
undifferentiated hESCs have few mitochondria with an
immature morphology, and a greater reliance on glycolysis
(St John et al., 2005; Oh et al., 2005; Cho et al., 2006). As
hESCs differentiate the number of mitochondria with a
mature morphology increases, as well as ATP production by
oxidative phosphorylation (Cho et al., 2006).
Finally, our results indicate that ROS produced at
complex III of the mitochondrial electron transfer chain
are at least partially responsible for the antimycin A effect
on Nanog expression. Mitochondrial ROS constitute the
major source of ROS in the cells and are produced as side
products of oxidative phosphorylation. The involvement of
ROS in deleterious processes such as DNA damage, changes
in the native structure of proteins, and lipidic peroxidation
of membranes has long been recognized. More recently,
however, it has been recognized that ROS can modulate
various intracellular signaling pathways through covalent
modifications (so-called “redox signaling”) of target mole-
cules, thereby inducing changes in cells that are important
in many physiological and pathophysiological processes
(Finkel, 2003). In addition, there is a growing body of
evidence that there is an increase in ROS production
following the addition of various peptide growth factors
to cells in culture, and that these ROS are a crucial
component of downstream signaling. Our results demon-
strate that antimycin A increases superoxide generation at
complex III and that capture of superoxide anion by MnTbap
partially abrogates the effect of antimycin A in Nanog
expression, suggesting ROS as at least a partial modulator of
antimycin A effect on pluripotency. Superoxide anion can
rapidly convert to other reactive species and therefore not
be captured by MnTbap, thus continuing to signal, which
might also explain why MnTbap does not completely
eliminate the antimycin A effect. This is in accordance
with the reports of Carriere et al. (Carriere et al., 2004)
demonstrating that antimycin A inhibited murine preadi-
pocyte differentiation toward the adipocyte phenotype by
increasing ROS formation at complex III. Indeed, several
growth factor and cytokines such as bFGF and TGFβ are
known to induce H2O2 generation in different cell types
(Thannickal and Fanburg, 2000). Alternatively, the effect
of antimycin A in Nanog expression could be a synergistic
action between ROS production and a shift in oxidative
metabolism toward glycolysis, which we have also demon-
strated to take place. This latter hypothesis is in accor-
dance with findings of Chung et al. (Chung et al., 2007) who
showed that during the in vitro process of mESC differen-
tiation, antimycin A inhibits oxidative phosphorylation and
leads to a reduced appearance of beating cardiomyocytes.
In addition, we cannot rule out the hypothesis that the
effect of antimycin A on Nanog expression could be partially
mediated by changes in calcium homeostasis. Indeed,
Spitkovsky et al. (Spitkovsky et al., 2004) demonstrated
that while antimycin A blocked cardiomyocyte differenti-
ation by acting on calcium signaling, the use of KCN (an
inhibitor of complex IV of the mitochondrial respiratory
153Mitochondria and embryonic stem cell pluripotencychain) did not. Further work is required to pinpoint the
exact mechanism(s) involved but our data provide the first
evidence that modulation of mitochondrial function (prob-
ably acting through a ROS-dependent pathway) can influ-
ence the pluripotent state of hESCs.
Materials and methods
Human embryonic stem cell culture
WA07 cells (WiCell) were cultured under normoxic conditions
(21% O2 and 5% CO2) in Knockout medium containing 80%
Knockout Dulbecco's modified Eagle's medium (DMEM)
(Invitrogen, Carslbad, CA) supplemented with 20% Knockout
Serum Replacer (Invitrogen), 1 mM L-glutamine, 4 ng/ml
basic human recombinant FGF, and 0.1 mM MEM nonessential
amino acids, 50 μg/ml penicillin, and 50 μg/ml streptomycin
(all from Invitrogen). Cells were passaged manually (Day 0)
using a pulled glass needle and then plated onto mitomycin
C-inactivated mouse embryonic fibroblast feeder cells
(Specialty Media, Phillipsburgh, NJ). On Day 2, 20 nM
antimycin A (Sigma-Aldrich, St. Louis, MO) was added and
media were changed every other day and new drug was
added. hESC culture on Matrigel (BD Biosciences) was
performed as described previously (Xu et al., 2001). Briefly,
human knockout medium was conditioned in MEFs and a total
of 8 ng bFGF/ml was used to supplement the media. Matrigel
was diluted according to manufacturer's instructions and was
allowed to coat dishes for at least 30 min at room
temperature before cells were added. In order to allow
cells to plate, treatments were initiated at Day 2 after
scraping and fresh media and drugs were added every other
day. MnTbap and PD173074 (Mohammadi et al., 1998; Ying et
al., 2008) were used at 50 μM and 100 nM, respectively.
Immunocytochemistry
Immunocytochemistry (ICC) for the standard pluripotency
markers Oct-4, Nanog, and SSEA-4 was assessed as previously
described (Navara et al., 2007). Only cells in which Oct-4 was
localized in the nucleus were considered positive for this
marker, whereas cytoplasmatic localization was considered
as negative.
RNA extraction, RT PCR, and TaqMan
low-density arrays
Total RNA extraction and PCR mixtures were prepared as
previously described (Navara et al., 2007). Real-time PCR
was performed using an ABI Prism 7700 (Applied Biosystems
Incorporated, Foster City, CA). Taqman gene expression
assays (Applied Biosystems) were used for Nanog, Oct-4, and
β actin. Water and no RT samples were used as negative
controls; all samples were run in triplicate. The TaqMan
array human stem cell pluripotency panel (Applied Biosys-
tems) was used following manufacturer's instructions. Nine
(FGF5, KRT1, GCM1, HBB, WT1, GCG, INS, IPF1, MYF5) genes
were excluded from our analysis due to very poor amplifi-
cation in any sample. mRNA fold changes were calculated
using the -ΔΔCt method and normalized using β actin
expression as endogenous control.Western blotting
hESCs were collected manually in PBS and pelleted. Total
protein extract was collected using RIPA buffer (Sigma)
supplemented with 1 mM PMSF. Protein quantification was
carried out using the Bradford assay (Bio-Rad Laboratories
Inc., CA) and 10 μg of protein was separated by 12% SDS-
PAGE. Primary antibodies used Nanog (Kamiya Biomedical
Company) and Oct-4 (Santa Cruz Biotechnology). ECL
Advance Western blot detection kit (Amersham Biosciences,
Piscataway, NJ) was used for detection.
Teratoma formation
hESCs treated for prolonged periods of time with 20 nM of
antimycin A either in the presence or in the absence of bFGF
were injected into the testis of nonobese diabetic/severe
combined immune deficient (NOD/SCID) mice. Three mice
were injected per experiment as previously described
(Navara et al., 2007).
Apoptosis/necrosis assay
hESCs were maintained on Matrigel and treated with
antimycin A as previously described and apoptosis/necrosis
rates were detected using the annexin V/PI apoptosis
detection kit (BD Biosciences) following the manufacturer's
instructions. Briefly, cells were washed with PBS and
dissociated with Accutase followed by two washes in cold
(4 °C) PBS. The amount of 1×106 cells was resuspended in
100 μl of binding buffer and 5 μl of both annexin V and PI was
added. The mixture was incubated for 15 min at 25 °C in the
dark followed by the addition of 400 μl binding buffer.
Labeled cells were analyzed by flow cytometry (BD LSR II, BD
Biosciences).
Measurement of hESC proliferation
hESC proliferation was determined by BrdU (Roche) incor-
poration into the genomic DNA during the S phase of the cell
cycle. hESCs maintained on Matrigel were treated with
antimycin A as previously described. At Day 6 after plating
hESCs were incubated in medium containing BrdU for 3 h and
washed three times with PBS. Cells were fixed and
incorporated BrdU was detected with Anti-BrdU according
to the manufacturer's instructions. Cells were imaged by
confocal microscopy and at least 2500 cells were counted to
determine number of cycling cells.
ATP measurement by HPLC
hESCs were maintained on Matrigel and antimycin A treated
as previously described. Intracellular adenine nucleotides
(ATP, ADP, and AMP) were determined as previously
described (Amaral et al., 2006). In brief, adenine nucleo-
tides were extracted with 0.6 M perchloric acid supple-
mented with 25 mM EDTA-Na. Cell supernatants were
neutralized with 3 M KOH in 1.5 M Tris followed by
centrifugation. Supernatants were assayed by HPLC.
The detection wavelength was 254 nm, and the column
was a Licophesfere100 RP108 5 μM (Merk). Adenylate
154 S. Varum et al.energy charge was calculated according to the following
formula: ATP+0.5×ADP/(ATP+ADP+AMP).
Lactate dehydrogenase activity
Lactate dehydrogenase activity was determined using the
QuantiChrom lactate dehydrogenase kit (Bio Assay Systems,
CA) following the manufacturer's instructions. Cells were
mechanically dissociated and lysed in 100 mM potassium
phosphate containing 2 mM EDTA buffer and centrifuged and
the resulting supernatants were assayed using the working
reagent. Optical density was read at 565 nm immediately
after the mixture of the sample and the working reagent, and
also 25min after addition. LDH activity was determined based
on the following formula: LDH activity=43.68×(OD S25–
ODS0)/(OD calibrator – OD H2O)×dilution factor.
Superoxide anion detection by MitoSox Red
hESCs were maintained on Matrigel for 7 days and treatments
(antimycin A and/or MnTbap) were initiated at Day 2 after
scraping. Fresh media and drugs were added every other day.
On Day 7, cells were washed with PBS and dissociated with
Accutase followed by two washes in PBS. Superoxide was
detected using MitoSox Red (Invitrogen). Cells were sus-
pended in media and incubated with 2.5 μM MitoSox Red for
30 min at 37 °C followed by one wash in PBS and subsequent
analysis by flow cytometry.
Statistical analysis
Means and standard error of the mean were calculated and
statistically significant differences were determined by
paired t test, chi-square test, or one-way ANOVA followed
by Dunnett's multiple comparison test. n refers to sample
size. Significance was determined at Pb0.05.
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